FDA Advocacy

Learn about our work to bring the voice of people concerned about women’s health to decision-makers who create and implement health policies.

Featured Posts

Sorry, we couldn't find any content.

Browse our FDA ADVOCACY work:

  • Filter by Category:

  • Sort by:

Results for:

As the United States nears the peak of the COVID-19 pandemic, it is natural to hope for treatments that can save lives. But when experimental drugs are promoted by a president who has consistently eschewed and misrepresented science, consumers and...

U.S. Food & Drug Administration Public Meeting on Testing Methods for Asbestos in Talc and Cosmetic Products Containing Talc

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org

Testimony Delivered at the Meeting of the FDA Bone, Reproductive and Urologic Drugs Advisory Committee

FDA Comments- Makena

By: Cindy Pearson , Testimony

[FDA-2019-N-4203] To Whom It May Concern: The National Women’s Health Network (NWHN) is a nonprofit advocacy organization that works to improve the health of all women. We are supported by our members and by choice, we do not accept financial...

The National Women’s Health Network (The NWHN) believes that more needs to be done to protect people against unnecessary harm caused by silicone gel-filled breast implants. Implants have been on the market for more than 30 years, and during that...

Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.

FOR IMMEDIATE RELEASE Contact: Evita Almassi, ealmassi@nwhn.org or 425-749-1886

The NWHN and 42 organizations sent a letter today to the House Energy and Commerce Committee applauding their work on a bipartisan discussion draft to address cosmetics safety.

Opioid dependency is a bodily adaptation that is likely to disproportionately affect women, because they are more likely to develop opioid dependency in a shorter period of time, compared to men.